Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials
Le-Rademacher J, Kanwar R, Seisler D, Pachman D, Qin R, Abyzov A, Ruddy K, Banck M, Lavoie Smith E, Dorsey S, Aaronson N, Sloan J, Loprinzi C, Beutler A. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Supportive Care In Cancer 2017, 25: 3537-3544. PMID: 28634656, PMCID: PMC5693734, DOI: 10.1007/s00520-017-3780-y.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyCTCAE gradePatient-reported outcomesQLQ-CIPN20Peripheral neuropathyClinical trialsNCI Common Terminology CriteriaCommon Terminology CriteriaMultivariable linear mixed modelsRecent clinical trialsTerminology CriteriaAdverse eventsCancer QualityClinical caveatsSerial assessmentClinical trial datasetPractice guidelinesIndividual patientsEuropean OrganizationCTCAEPatientsOutcome variablesStrong positive associationLinear mixed modelsNeuropathy